Vascular Endothelial Growth Factor (VEGF) is a key protein involved in the development and progression of liver tumors, especially **hepatocellular carcinoma (HCC)**, which is the most common type of primary liver cancer. VEGF promotes **angiogenesis**, the formation of new blood vessels, which is critical for tumor growth, invasion, and metastasis.
Vascular Endothelial Growth Factor (VEGF) is a key protein involved in the development and progression of liver tumors, especially **hepatocellular carcinoma (HCC)**, which is the most common type of primary liver cancer. VEGF promotes **angiogenesis**, the formation of new blood vessels, which is critical for tumor growth, invasion, and metastasis. It binds to specific receptors, such as VEGFR-2, to stimulate endothelial cell proliferation, vascular remodeling, and increased vascular permeability. This process provides oxygen and nutrients to the tumor, enabling its rapid growth.
In liver tumors like HCC, VEGF is often overexpressed, especially under **hypoxic conditions** (low oxygen), which are common in growing tumors. Hypoxia triggers the release of VEGF through the activation of **Hypoxia-Inducible Factor-1α (HIF-1α)**. VEGF also contributes to **portal vein tumor thrombosis (PVTT)**, a severe complication in HCC, and promotes the spread of secondary liver tumors (metastases) by enhancing vascularization.
VEGF is not only a marker of poor prognosis, as its high levels correlate with larger tumors, vascular invasion, and metastasis, but it also serves as a major therapeutic target. Anti-VEGF therapies have transformed the treatment of advanced liver tumors. Examples include **bevacizumab**, a monoclonal antibody targeting VEGF-A, and **tyrosine kinase inhibitors (TKIs)** like **sorafenib** and **lenvatinib**, which block VEGF receptors and other angiogenic pathways. Combination therapies, such as **atezolizumab (anti-PD-L1) and bevacizumab**, have shown superior efficacy in managing advanced HCC by combining VEGF inhibition with immune checkpoint blockade.
Despite their benefits, VEGF-targeted therapies face challenges like **resistance** (activation of alternative angiogenic pathways) and **toxicity** (e.g., hypertension, bleeding). Future directions focus on developing predictive biomarkers to select the right patients, combining VEGF inhibitors with other treatments, and personalizing therapies based on tumor profiles.
In summary, VEGF plays a central role in liver tumor biology, and targeting it has become a cornerstone of treatment, particularly for advanced HCC. However, ongoing research aims to address resistance and improve outcomes through innovative strategies.
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.